<DOC>
	<DOCNO>NCT02859077</DOCNO>
	<brief_summary>BIM deletion polymorphism might associate poor clinical response EGFR-TKIs patient NSCLC EGFR mutation . In study , investigator want use EGFR-TKI chemotherapy first line treatment stage IIIB/IV NSCLC patient EGFR mutation BIM deletion polymorphism .</brief_summary>
	<brief_title>EGFR-TKI With Chemotherapy NSCLC Patients With Both EGFR Mutation BIM Deletion Polymorphism</brief_title>
	<detailed_description>BIM deletion polymorphism poor clinical response marker EGFR-TKIs NSCLC patient EGFR mutation . In study , investigator want use EGFR-TKI chemotherapy 1 st treatment stage IIIB/IV NSCLC patient EGFR mutation BIM deletion polymorphism .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed informed consent Age &gt; =18 year Histologically document , unresectable , inoperable , locally advanced , recurrent metastatic Stage IV NonSmall Cell Lung Cancer ( NSCLC ) A cytologic diagnosis acceptable ( i.e. , FNA pleural fluid cytology ) Must measurable nonmeasurable disease Must able comply study followup procedure Small cell , carcinoid , mixed small cell lung cancer Malignancies within 3 year except adequately treat carcinoma situ cervix basal squamous cell skin cancer Symptomatic untreated brain metastasis Prior systemic chemotherapy NSCLC Unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , serious cardiac arrhythmia require medication ( patient chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia , eligible ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Gastrointestinal tract disease result inability take oral medication requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>BIM</keyword>
	<keyword>EGFR mutation</keyword>
</DOC>